ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Collagenase-Coated Polymeric Drug/siRNA Nanoparticles Overcome ECM and Regulate Metabolic Reprogramming of Fibroblasts for Alleviating Pulmonary Fibrosis.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Pulmonary fibrosis (PF) is a progressive lung disease characterized by abnormal extracellular matrix (ECM) accumulation, leading to respiratory dysfunction and eventual respiratory failure. The pathogenesis involves fibroblast migration, proliferation, and activation via the CXCL12/CXCR4 axis, resulting in collagen deposition and ECM accumulation. Additionally, this axis drives epithelial-mesenchymal transition (EMT) and angiogenesis. Under hypoxic conditions induced by ECM accumulation, pyruvate dehydrogenase kinase 1 (PDK1) further promotes fibroblasts differentiation into myofibroblasts by enhancing metabolic reprogramming towards glycolysis. To target these multifaceted pathological processes, a collagenase-coated polymeric drug/siRNA delivery system is engineered. This system comprises PPLFazo, hypoxia-responsive polymer of plerixafor (CXCR4 inhibitor), loaded with PDK1 siRNA (siPDK1) and encapsulated by collagenase-conjugated polyglutamic acid. Upon inhalation, the collagenase degrades ECM barrier, facilitating PPLFazo/siPDK1 recognition and endocytosis by fibroblasts. In the hypoxic microenvironment, both plerixafor monomers and siPDK1 are released, exerting their targeted therapeutic effects. Pharmacodynamic evaluations in murine PF models demonstrated that PPLFazo/siPDK1@G-CLG reduced myofibroblast accumulation, decreased collagen deposition, and attenuated abnormal fibrotic tissue growth in the lungs. These findings collectively indicate substantial amelioration of PF. By simultaneously targeting multiple pathological pathways, this system offers a novel strategy to combat this challenging disease, potentially improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.